Sermorelin is a 29 amino acid growth hormone-releasing hormone (GHRH) analogue administered as a nightly subcutaneous injection to stimulate the pituitary’s own growth hormone production. Standard starting doses range from 200 to 300 mcg per injection, titrated upward based on IGF-1 response and symptom assessment. Results are gradual: most patients notice improved sleep quality within 3 to 4 weeks, body composition changes at 3 to 6 months, and full therapeutic benefit at 6 to 12 months of consistent therapy. Understanding the realistic timeline and what monitoring is required prevents the most common cause of treatment failure: stopping too early.
What Is Sermorelin and How Is It Administered?
Sermorelin acetate is a compounded peptide available as a lyophilized (freeze-dried) powder that is reconstituted with bacteriostatic water and stored refrigerated. It is administered via subcutaneous injection using a small insulin-gauge needle (typically 29 to 31 gauge, 5/16 inch) into the abdominal fat or thigh. The injection is essentially painless for most patients due to the small needle size and subcutaneous — rather than intramuscular — route.
Administration timing is clinically significant. Sermorelin is almost universally prescribed for nightly use, administered 30 to 60 minutes before sleep. This timing aligns the drug’s stimulatory effect on the pituitary with the body’s natural peak in growth hormone secretion, which occurs during slow-wave (deep) sleep. Evening administration also avoids the inhibitory effect of postprandial insulin, which suppresses GH release, and takes advantage of lower circulating somatostatin in the evening hours.
For optimal response, sermorelin should be injected at least 2 hours after the last meal. Elevated insulin from recent food intake suppresses GH secretion and reduces sermorelin’s pituitary stimulatory effect. Patients who inject immediately after dinner typically see weaker IGF-1 responses than those who allow a post-meal interval. Some protocols specify a 3-hour post-meal window for patients who are poor responders at standard dosing.
Sermorelin Dosage: Standard Protocols and Titration
Sermorelin dosing is not standardized across all providers because it remains a compounded medication without an approved adult indication. The protocols described below reflect common clinical practice; individual physicians may use variations based on patient response, weight, and IGF-1 targets.
Starting dose
Most protocols initiate sermorelin at 200 to 300 mcg per nightly injection. This dose is sufficient to produce a measurable pituitary response in most adults with adequate pituitary reserve. Lower starting doses (100 to 150 mcg) are sometimes used in older patients or those with suspected pituitary sensitivity, with upward titration after the first IGF-1 check at 6 to 8 weeks.
Titration based on IGF-1
IGF-1 is the primary biomarker used to assess sermorelin response and guide dose adjustments. The clinical target is typically the upper third of the age-adjusted reference range for IGF-1. If IGF-1 remains in the lower half of the reference range after 6 to 8 weeks at starting dose, the dose is increased by 100 mcg increments up to a maximum of 500 to 600 mcg per night in most protocols. If IGF-1 rises above the upper limit of normal, the dose is reduced.
Dose frequency
Standard sermorelin protocols use nightly dosing 5 to 7 days per week. Some physicians prescribe 5 days on and 2 days off to allow the pituitary’s GHRH receptor to avoid tachyphylaxis (receptor desensitization from continuous stimulation). Whether cycling prevents meaningful receptor downregulation at standard doses is debated in the clinical literature, but the 5-on-2-off approach is widely used as a precaution.
| Protocol Phase | Dose Range | Frequency | IGF-1 Target |
|---|---|---|---|
| Initiation Weeks 1 to 8 |
200 to 300 mcg nightly | 5 to 7 nights per week | First check at week 6 to 8 |
| Dose optimization Months 2 to 4 |
200 to 500 mcg nightly | 5 to 7 nights per week | Upper third of age-adjusted range |
| Maintenance Month 4 onwards |
Individually optimized dose | 5 nights per week (5-on-2-off) | IGF-1 within age-adjusted range |
| Maximum dose | 500 to 600 mcg nightly | Not exceeded without specialist review | IGF-1 must not exceed upper limit of normal |
Results Timeline: What to Expect Month by Month
Sermorelin produces benefits gradually and sequentially. The order in which benefits appear reflects the underlying physiology: sleep architecture and recovery improve first because they are most sensitive to GH pulsatility; body composition changes require sustained anabolic signaling over months; and structural benefits such as skin quality and joint health are last because they depend on cumulative IGF-1 exposure over time.
Sermorelin Results Timeline: What to Expect
Timeline reflects typical patient experience. Individual results vary based on age, dose, pituitary function, lifestyle, and adherence to protocol.
Who Responds Best to Sermorelin
Not all patients respond equally to sermorelin. The strength of response depends primarily on the pituitary’s capacity to respond to GHRH stimulation. Several patient characteristics predict better or worse outcomes.
Strongest predictors of good response
- Age under 60 with intact pituitary function. Younger patients typically have greater residual pituitary responsiveness to GHRH. Patients over 65 may need higher doses or longer titration periods to achieve equivalent IGF-1 responses.
- Secondary growth hormone decline (somatopause) rather than structural pituitary disease. Men whose GH decline is age-related respond more consistently than those with pituitary pathology, where the gland’s capacity to respond is structurally limited.
- Low baseline IGF-1 in the lower half of the age-adjusted range. These patients have the most room to benefit and show the clearest IGF-1 response to titration.
- Consistent lifestyle factors. Adequate sleep (7 to 9 hours), resistance training, and controlled body fat percentage amplify sermorelin’s effects by optimizing the hormonal environment in which it operates.
Factors associated with reduced response
- Obesity (BMI above 30). Adipose tissue contains somatostatin-secreting cells that blunt GH pulsatility. Elevated circulating free fatty acids in obese individuals also suppress GH release. Weight reduction often dramatically improves sermorelin response in overweight patients.
- Hypothyroidism. Thyroid hormone is required for normal GH signaling. Patients with untreated or undertreated hypothyroidism show blunted IGF-1 responses to sermorelin.
- Chronic elevated cortisol. Cortisol suppresses GH secretion. Patients under significant chronic stress or on glucocorticoid medications may respond poorly until the cortisol burden is reduced.
- Poor sleep quality or untreated sleep apnea. Since sermorelin works primarily through the nocturnal GH peak, fragmented sleep significantly reduces its efficacy.
Sermorelin Side Effects: What Is Clinically Documented
Sermorelin’s side effect profile is generally mild, which reflects the self-limiting nature of its mechanism. Because somatostatin feedback prevents supraphysiologic IGF-1, the side effects associated with excessive growth hormone (fluid retention, carpal tunnel syndrome, insulin resistance) are substantially less common than with exogenous HGH.
Sermorelin Side Effects by Frequency
Any therapy that increases growth factor activity is contraindicated in patients with active cancer or a history of IGF-1-sensitive tumors. Pituitary adenoma must be ruled out before starting sermorelin, as stimulating a tumor-bearing pituitary could accelerate adenoma growth. A baseline MRI of the pituitary is not universally required before sermorelin but is appropriate in patients with unexplained very low IGF-1, elevated prolactin, visual field changes, or headaches that may suggest pituitary pathology. Inform your physician of any personal or family history of cancer before starting therapy.
Lab Monitoring During Sermorelin Therapy
Safe and effective sermorelin therapy requires regular laboratory assessment. The monitoring protocol is less intensive than for exogenous HGH but is not optional. Skipping labs removes the only objective evidence of whether therapy is working and whether dosing is within safe parameters.
| Lab Test | Timing | Purpose | Action Threshold |
|---|---|---|---|
| IGF-1 | Baseline, 6 to 8 weeks, then every 3 to 6 months | Primary efficacy and safety marker | Reduce dose if above upper limit of normal; increase if in lower third at 8 weeks |
| Fasting glucose and HbA1c | Baseline, 3 months, then annually | Monitor insulin sensitivity | Significant rise warrants dose reduction or protocol review |
| TSH | Baseline | Rule out hypothyroidism as cause of poor response | Treat thyroid before optimizing sermorelin |
| Cortisol (AM) | Baseline if poor response | Identify cortisol-driven GH suppression | Elevated cortisol requires addressing before dose escalation |
| PSA (men over 40) | Baseline, annually | Prostate monitoring in IGF-1-elevating therapy | Rise above 1.4 ng/mL from baseline warrants urological review |
Growth hormone’s anabolic effects are amplified by resistance training, adequate protein intake (1.6 to 2.2g per kg body weight), and 7 to 9 hours of quality sleep. Sermorelin patients who do not train and do not address sleep hygiene see substantially weaker body composition results than those who do. The drug provides the hormonal signal; the body’s response depends on having the substrate and recovery conditions to use that signal effectively. Addressing sleep apnea, reducing alcohol, and managing body weight all improve both sermorelin response and the outcomes of concurrent hormone therapies.
Sermorelin vs HGH: Choosing the Right Approach
For men whose primary concern is age-related growth hormone decline with a functioning pituitary, sermorelin is the more appropriate starting point before considering exogenous HGH. It is safer, less expensive, legal to prescribe off-label, and produces physiologic rather than pharmacologic IGF-1 elevations. Men who do not respond to adequately dosed sermorelin after 4 to 6 months may have insufficient pituitary reserve and should be evaluated for adult growth hormone deficiency via stimulation testing before exogenous HGH is considered.
For a complete comparison of sermorelin and HGH including mechanism of action, legal status, cost breakdown, and safety data, see our detailed guide on sermorelin vs HGH: benefits, cost and which is safer.
Get Started With a Supervised Sermorelin Protocol
Advanced TRT Clinic provides physician-supervised peptide and hormone optimization therapy via telemedicine, including sermorelin protocols, lab coordination, dose titration, and ongoing clinical management. Availability varies by state.
